They have structured the NYR drug to be in essence doing a...

They have structured the NYR drug to be in essence doing a similar job as NSAIDS (anti inflammatories for the body) but targets inflammation channels in the brain and the uniqueness of NYR is it crosses the blood brain barrier to target these specific receptors after a knock to the head has happened

The drug works, its acute therapy and safety profile has already been assessed in previous pre clinical study.

- Let the GLP results coming out near term which will be the same as pre clinical study because they specifically assessed this parameter in those studies hence de risked

- Acute therapy like this drug has significantly reduced risk for side effects in humans compared to chronic treatment and the target of these inflammatory receptors working similar to how NSAIDS work in the body mitigates this risk

- Proven efficacy already and how the drug functions means Walter Reed will be a success and let the US department of defence contract flourish

Let the next 1-3 months come in because this isn’t a 10 million dollar market cap with 10 million in funding when peers in the same space are 70-100 million dollar market caps after pre clinical success but it will come either way in the period ahead and once phase 1 is complete with Walter Reed and IND for phase 2 is in the skies the limit for this one and north of 100 million dollar valuation is coming in very quickly